PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced that its Board of Directors (the “Board”) has authorized…Read More
Pasithea Therapeutics Announces Intention to Commence a 40 Million Tender Offer for its Common Stock at Price of 070 per Share in Cash
